一项1期临床试验显示sc-rAAV2.5IL-1Ra在人类骨关节炎膝关节内安全、持续表达
这项1期开放标签临床试验纳入9例影像学膝关节骨关节炎患者,将编码人IL-1Ra的自互补重组腺相关病毒2.5型(sc-rAAV2.5IL-1Ra)以低(1×10^11 vg)、中(1×10^12 vg)或高(1×10^13 vg)剂量关节腔内注射至指标膝关节,主要终点为安全性。结果无与sc-rAAV2.5IL-1Ra相关的严重不良事件,2例可能相关不良事件均为积液伴疼痛加重并经保守治疗缓解;所有患者滑液中IL-1Ra浓度升高且1年后仍保持升高,研究期间基线疼痛和功能评分改善。
要点
- 9例影像学膝关节骨关节炎患者接受sc-rAAV2.5IL-1Ra关节腔内注射,剂量为1×10^11、1×10^12或1×10^13 vg。
- 无与sc-rAAV2.5IL-1Ra相关的严重不良事件;2例可能相关不良事件均为积液伴疼痛加重,经保守治疗缓解。
- 所有患者滑液中IL-1Ra浓度升高且1年后仍保持升高,研究期间基线疼痛和功能评分改善。
核心结论
- 关节腔内注射sc-rAAV2.5IL-1Ra基因治疗是安全的,人膝关节局部IL-1Ra持续升高支持进一步临床检查该疗法以期为骨关节炎提供治疗获益。
研究设计与样本
- 1期开放标签临床试验,纳入9例影像学膝关节骨关节炎患者。
- 通过关节腔内注射将sc-rAAV2.5IL-1Ra递送至指标膝关节,剂量为低(1×10^11 vg)、中(1×10^12 vg)或高(1×10^13 vg)三档之一。
- 主要终点为安全性。
主要发现
- 无与sc-rAAV2.5IL-1Ra相关的严重不良事件;2例可能相关不良事件均为积液伴疼痛加重,经保守治疗缓解。
- sc-rAAV2.5IL-1Ra未引起生命体征、体格检查或临床实验室指标变化。
- 注射后1天在循环中检测到的sc-rAAV2.5IL-1Ra病毒基因组低于注射剂量的1%,并在一周内清除。
- 血清和滑液中抗AAV2.5中和抗体滴度升高。
- 所有患者滑液中IL-1Ra浓度升高,且1年后IL-1Ra浓度仍保持升高;研究期间基线疼痛和功能评分改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoarthritis (OA) is a major global health problem with no disease-modifying therapies. Interleukin-1 (IL-1) is a critical cytokine associated with the pathophysiology of OA and can be inhibited by IL-1 receptor antagonist (IL-1Ra). Here, we tested the delivery of a gene therapeutic encoding the human IL-1Ra to the knee in a phase 1, open-label clinical trial that enrolled nine patients with radiographic knee OA. The IL-1Ra gene was delivered by a self-complementary (sc)-recombinant adeno-associated virus (rAAV) serotype 2.5 (sc-rAAV2.5IL-1Ra) by intra-articular injection into an index knee at one of three doses: low [1 × 1011 viral genomes (vg)], mid (1 × 1012 vg), or high (1 × 1013 vg). The primary outcome was safety. There were no serious adverse events (AEs) related to sc-rAAV2.5IL-1Ra. Two AEs occurred that were possibly related to the vector. Both were effusions with increased pain and resolved with conservative treatment. sc-rAAV2.5IL-1Ra did not cause changes in vital signs, physical findings, or clinical laboratory measures. Less than 1% of the injected dose of sc-rAAV2.5IL-1Ra vg was detected in circulation after 1 day and was cleared within a week. Titers of neutralizing antibodies to AAV2.5 rose in serum and synovial fluid. In all cases, IL-1Ra concentration increased in the synovial fluid, and IL-1Ra concentrations remained elevated after 1 year. Baseline pain and function scores improved during the study. Therefore, we found that intra-articular gene therapy with sc-rAAV2.5IL-1Ra was safe. The sustained increase in local IL-1Ra in human knee joints supports the further clinical examination of this therapy to provide therapeutic benefit in OA.
引用
- De la Vega RE, Sellon JL, Smith J, et al. A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint. Sci Transl Med. 2025. PMID: 40465688. doi:10.1126/scitranslmed.adu9804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。